Tay Therapeutics is a UK biotech based in Dundee with facilities overlooking the River Tay. Dedicated to developing new therapeutics for unmet medical needs, we bridge the divide between the discovery of medicines and patients.
Our business model is to target defined patient subgroups with differentiated small molecule therapeutics. To achieve this goal, we partner selected assets with companies possessing capabilities and expertise to maximise the value of Tay’s pipeline.
Tay Therapeutics’ model is validated by a partnership with Vyne Therapeutics, a NASDAQ listed biotech developing novel therapies for immune-inflammatory conditions (vynetherapeutics.com).
Tay Therapeutics is now developing its next pipeline assets by targeting stop codon mutations in cancer and genetic diseases.
Since inception and spinout from the University of Dundee, Tay Therapeutics (formerly known as In4Derm) has been supported by seed investment from o2h Ventures, Meltwind, Wren Capital, University of Dundee and Scottish Enterprise. Coupled to license revenues from its BETi programmes and grants, Tay has developed a coveted pipeline of assets in a very capital efficient way. Tay plans to continue using license revenues to support the development of its portfolio of programmes but will seek to raise Series A investment in 2024 to move its programmes into clinical development.